Article Text

PDF
SP0134 INTERLEUKIN-2 therapy in sle
  1. JY Humrich
  1. Department of Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

Abstract

There is an unmet need for more effective and selective therapeutics in severe autoimmune diseases such as systemic lupus erythematosus (SLE). A deeper understanding of the pathogenic mechanisms in the past has led to the clinical translation of low-dose interleukin-2 (IL-2) therapy which primarily aims to restore the activity of regulatory T cells. First results from phase I/II studies are promising by proving the selective expansion of regulatory T cells in vivo and by providing first evidence for the clinical efficacy of low-dose IL-2 therapy in SLE. Here we will summarize key findings which led to the development of this novel therapeutic concept and will highlight the main rationales for the clinical translation of low-dose IL-2 therapy in SLE.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.